Bruce Booth, D.Phil. has served as a member of our board of directors since June 2020. Dr. Booth joined Atlas Venture in 2005 and currently serves as general partner. Dr. Booth co-founded Kymera Therapeutics, Inc. (NASDAQ: KYMR) and has served as chairman of its board of directors since April 2016. Dr. Booth is chair or a member of the boards of directors of several private companies, including Nimbus Therapeutics, LLC, HotSpot Therapeutics, Inc., and Matchpoint Therapeutics, Inc. Dr. Booth previously served on the boards of directors of AVROBIO, Inc. (now Tectonic Therapeutic, Inc. (NASDAQ: TECX)) from February 2016 to June 2024, Magenta Therapeutics, Inc. (now Dianthus Therapeutics, Inc. (NASDAQ: DNTH)) from February 2016 to September 2023, Vigil Neuroscience, Inc. (NASDAQ: VIGL) from June 2020 to August 2025 and several private companies. Dr. Booth earned a B.S. in biochemistry, summa cum laude, from Pennsylvania State University. Dr. Booth was a British Marshall Scholar and earned a D.Phil. in molecular immunology from Oxford University s Nuffield Department of Medicine. We believe Dr. Booth s extensive leadership, executive, managerial and business experience with life sciences companies and experience as a public company board member provide him with the appropriate set of skills to serve as a member of our board of directors.